Middle East respiratory syndrome coronavirus: current situation and travel-associated concerns
dc.contributor.author | Al-Tawfiq, Jaffar A. | |
dc.contributor.author | Omrani, Ali S. | |
dc.contributor.author | Memish, Ziad A. | |
dc.contributor.department | Medicine, School of Medicine | en_US |
dc.date.accessioned | 2020-04-01T10:20:42Z | |
dc.date.available | 2020-04-01T10:20:42Z | |
dc.date.issued | 2016 | |
dc.description | This article is made available for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. | |
dc.description.abstract | The emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 brought back memories of the occurrence of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002. More than 1500 MERS-CoV cases were recorded in 42 months with a case fatality rate (CFR) of 40%. Meanwhile, 8000 cases of SARS-CoV were confirmed in six months with a CFR of 10%. The clinical presentation of MERS-CoV ranges from mild and non-specific presentation to progressive and severe pneumonia. No predictive signs or symptoms exist to differentiate MERS-CoV from community-acquired pneumonia in hospitalized patients. An apparent heterogeneity was observed in transmission. Most MERS-CoV cases were secondary to large outbreaks in healthcare settings. These cases were secondary to community-acquired cases, which may also cause family outbreaks. Travel-associated MERS infection remains low. However, the virus exhibited a clear tendency to cause large outbreaks outside the Arabian Peninsula as exemplified by the outbreak in the Republic of Korea. In this review, we summarize the current knowledge about MERS-CoV and highlight travel-related issues. | en_US |
dc.identifier.citation | Al-Tawfiq, J. A., Omrani, A. S., & Memish, Z. A. (2016). Middle East respiratory syndrome coronavirus: current situation and travel-associated concerns. Frontiers of medicine, 10(2), 111–119. https://doi.org/10.1007/s11684-016-0446-y | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/22440 | |
dc.language.iso | en_US | en_US |
dc.publisher | Springer Nature | en_US |
dc.relation.isversionof | 10.1007/s11684-016-0446-y | en_US |
dc.relation.journal | Frontiers of Medicine | en_US |
dc.rights | Publisher Policy | en_US |
dc.rights | This article is made available for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. | |
dc.source | PMC | en_US |
dc.subject | Coronavirus | en_US |
dc.subject | MERS | en_US |
dc.subject | Middle East Respiratory Syndrome Coronavirus | en_US |
dc.subject | MERS-CoV | en_US |
dc.title | Middle East respiratory syndrome coronavirus: current situation and travel-associated concerns | en_US |
dc.type | Article | en_US |